Estimating the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis
Summary Based on a population age 50+, significant excess costs relative to matched controls exist for patients with incident fractures that are similar in relative magnitude to other chronic diseases such as stroke or heart disease. Prevalent fractures also have significant excess costs that are si...
Saved in:
Published in: | Osteoporosis international Vol. 24; no. 2; pp. 581 - 593 |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
London
Springer-Verlag
01-02-2013
Springer Nature B.V |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Summary
Based on a population age 50+, significant excess costs relative to matched controls exist for patients with incident fractures that are similar in relative magnitude to other chronic diseases such as stroke or heart disease. Prevalent fractures also have significant excess costs that are similar in relative magnitude to asthma/chronic obstructive pulmonary disease.
Introduction
Cost of illness studies for osteoporosis that only include incident fractures may ignore the long-term cost of prevalent fractures and primary preventive care. We estimated the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis relative to matched controls.
Methods
Men and women age 50+ were selected from administrative records in the province of Manitoba, Canada for the fiscal year 2007–2008. Three types of cases were identified: (1) patients with incident fractures in the current year (2007–2008), (2) patients with prevalent fractures in previous years (1995–2007), and (3) nonfracture osteoporosis patients identified by specific pharmacotherapy or low bone mineral density. Excess resource utilization and costs were estimated by subtracting control means from case means.
Results
Seventy-three percent of provincial population age 50+ (52 % of all men and 91 % of all women) were included (121,937 cases, 162,171 controls). There were 3,776 cases with incident fracture (1,273 men and 2,503 women), 43,406 cases with prevalent fractures (15,784 men and 27,622 women) and 74,755 nonfracture osteoporosis cases (7,705 men and 67,050 women). All incident fractures had significant excess costs. Incident hip fractures had the highest excess cost: men $44,963 (95 % CI: $38,498–51,428) and women $45,715 (95 % CI: $36,998–54,433). Prevalent fractures (other than miscellaneous or wrist fractures) also had significant excess costs. No significant excess costs existed for nonfracture osteoporosis.
Conclusion
Significant excess costs exist for patients with incident fractures and with prevalent hip, vertebral, humerus, multiple, and traumatic fractures. Ignoring prevalent fractures underestimate the true cost of osteoporosis. |
---|---|
AbstractList | Based on a population age 50+, significant excess costs relative to matched controls exist for patients with incident fractures that are similar in relative magnitude to other chronic diseases such as stroke or heart disease. Prevalent fractures also have significant excess costs that are similar in relative magnitude to asthma/chronic obstructive pulmonary disease. Introduction: Cost of illness studies for osteoporosis that only include incident fractures may ignore the long-term cost of prevalent fractures and primary preventive care. We estimated the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis relative to matched controls. Methods: Men and women age 50+ were selected from administrative records in the province of Manitoba, Canada for the fiscal year 2007-2008. Three types of cases were identified: (1) patients with incident fractures in the current year (2007-2008), (2) patients with prevalent fractures in previous years (1995-2007), and (3) nonfracture osteoporosis patients identified by specific pharmacotherapy or low bone mineral density. Excess resource utilization and costs were estimated by subtracting control means from case means. Results: Seventy-three percent of provincial population age 50+ (52 % of all men and 91 % of all women) were included (121,937 cases, 162,171 controls). There were 3,776 cases with incident fracture (1,273 men and 2,503 women), 43,406 cases with prevalent fractures (15,784 men and 27,622 women) and 74,755 nonfracture osteoporosis cases (7,705 men and 67,050 women). All incident fractures had significant excess costs. Incident hip fractures had the highest excess cost: men $44,963 (95 % CI: $38,498-51,428) and women $45,715 (95 % CI: $36,998-54,433). Prevalent fractures (other than miscellaneous or wrist fractures) also had significant excess costs. No significant excess costs existed for nonfracture osteoporosis. Conclusion: Significant excess costs exist for patients with incident fractures and with prevalent hip, vertebral, humerus, multiple, and traumatic fractures. Ignoring prevalent fractures underestimate the true cost of osteoporosis. Based on a population age 50+, significant excess costs relative to matched controls exist for patients with incident fractures that are similar in relative magnitude to other chronic diseases such as stroke or heart disease. Prevalent fractures also have significant excess costs that are similar in relative magnitude to asthma/chronic obstructive pulmonary disease. Cost of illness studies for osteoporosis that only include incident fractures may ignore the long-term cost of prevalent fractures and primary preventive care. We estimated the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis relative to matched controls. Men and women age 50+ were selected from administrative records in the province of Manitoba, Canada for the fiscal year 2007-2008. Three types of cases were identified: (1) patients with incident fractures in the current year (2007-2008), (2) patients with prevalent fractures in previous years (1995-2007), and (3) nonfracture osteoporosis patients identified by specific pharmacotherapy or low bone mineral density. Excess resource utilization and costs were estimated by subtracting control means from case means. Seventy-three percent of provincial population age 50+ (52 % of all men and 91 % of all women) were included (121,937 cases, 162,171 controls). There were 3,776 cases with incident fracture (1,273 men and 2,503 women), 43,406 cases with prevalent fractures (15,784 men and 27,622 women) and 74,755 nonfracture osteoporosis cases (7,705 men and 67,050 women). All incident fractures had significant excess costs. Incident hip fractures had the highest excess cost: men $44,963 (95 % CI: $38,498-51,428) and women $45,715 (95 % CI: $36,998-54,433). Prevalent fractures (other than miscellaneous or wrist fractures) also had significant excess costs. No significant excess costs existed for nonfracture osteoporosis. Significant excess costs exist for patients with incident fractures and with prevalent hip, vertebral, humerus, multiple, and traumatic fractures. Ignoring prevalent fractures underestimate the true cost of osteoporosis.[PUBLICATION ABSTRACT] SUMMARYBased on a population age 50+, significant excess costs relative to matched controls exist for patients with incident fractures that are similar in relative magnitude to other chronic diseases such as stroke or heart disease. Prevalent fractures also have significant excess costs that are similar in relative magnitude to asthma/chronic obstructive pulmonary disease. INTRODUCTIONCost of illness studies for osteoporosis that only include incident fractures may ignore the long-term cost of prevalent fractures and primary preventive care. We estimated the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis relative to matched controls. METHODSMen and women age 50+ were selected from administrative records in the province of Manitoba, Canada for the fiscal year 2007-2008. Three types of cases were identified: (1) patients with incident fractures in the current year (2007-2008), (2) patients with prevalent fractures in previous years (1995-2007), and (3) nonfracture osteoporosis patients identified by specific pharmacotherapy or low bone mineral density. Excess resource utilization and costs were estimated by subtracting control means from case means. RESULTSSeventy-three percent of provincial population age 50+ (52 % of all men and 91 % of all women) were included (121,937 cases, 162,171 controls). There were 3,776 cases with incident fracture (1,273 men and 2,503 women), 43,406 cases with prevalent fractures (15,784 men and 27,622 women) and 74,755 nonfracture osteoporosis cases (7,705 men and 67,050 women). All incident fractures had significant excess costs. Incident hip fractures had the highest excess cost: men $44,963 (95 % CI: $38,498-51,428) and women $45,715 (95 % CI: $36,998-54,433). Prevalent fractures (other than miscellaneous or wrist fractures) also had significant excess costs. No significant excess costs existed for nonfracture osteoporosis. CONCLUSIONSignificant excess costs exist for patients with incident fractures and with prevalent hip, vertebral, humerus, multiple, and traumatic fractures. Ignoring prevalent fractures underestimate the true cost of osteoporosis. Summary Based on a population age 50+, significant excess costs relative to matched controls exist for patients with incident fractures that are similar in relative magnitude to other chronic diseases such as stroke or heart disease. Prevalent fractures also have significant excess costs that are similar in relative magnitude to asthma/chronic obstructive pulmonary disease. Introduction Cost of illness studies for osteoporosis that only include incident fractures may ignore the long-term cost of prevalent fractures and primary preventive care. We estimated the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis relative to matched controls. Methods Men and women age 50+ were selected from administrative records in the province of Manitoba, Canada for the fiscal year 2007–2008. Three types of cases were identified: (1) patients with incident fractures in the current year (2007–2008), (2) patients with prevalent fractures in previous years (1995–2007), and (3) nonfracture osteoporosis patients identified by specific pharmacotherapy or low bone mineral density. Excess resource utilization and costs were estimated by subtracting control means from case means. Results Seventy-three percent of provincial population age 50+ (52 % of all men and 91 % of all women) were included (121,937 cases, 162,171 controls). There were 3,776 cases with incident fracture (1,273 men and 2,503 women), 43,406 cases with prevalent fractures (15,784 men and 27,622 women) and 74,755 nonfracture osteoporosis cases (7,705 men and 67,050 women). All incident fractures had significant excess costs. Incident hip fractures had the highest excess cost: men $44,963 (95 % CI: $38,498–51,428) and women $45,715 (95 % CI: $36,998–54,433). Prevalent fractures (other than miscellaneous or wrist fractures) also had significant excess costs. No significant excess costs existed for nonfracture osteoporosis. Conclusion Significant excess costs exist for patients with incident fractures and with prevalent hip, vertebral, humerus, multiple, and traumatic fractures. Ignoring prevalent fractures underestimate the true cost of osteoporosis. Based on a population age 50+, significant excess costs relative to matched controls exist for patients with incident fractures that are similar in relative magnitude to other chronic diseases such as stroke or heart disease. Prevalent fractures also have significant excess costs that are similar in relative magnitude to asthma/chronic obstructive pulmonary disease. Cost of illness studies for osteoporosis that only include incident fractures may ignore the long-term cost of prevalent fractures and primary preventive care. We estimated the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis relative to matched controls. Men and women age 50+ were selected from administrative records in the province of Manitoba, Canada for the fiscal year 2007-2008. Three types of cases were identified: (1) patients with incident fractures in the current year (2007-2008), (2) patients with prevalent fractures in previous years (1995-2007), and (3) nonfracture osteoporosis patients identified by specific pharmacotherapy or low bone mineral density. Excess resource utilization and costs were estimated by subtracting control means from case means. Seventy-three percent of provincial population age 50+ (52 % of all men and 91 % of all women) were included (121,937 cases, 162,171 controls). There were 3,776 cases with incident fracture (1,273 men and 2,503 women), 43,406 cases with prevalent fractures (15,784 men and 27,622 women) and 74,755 nonfracture osteoporosis cases (7,705 men and 67,050 women). All incident fractures had significant excess costs. Incident hip fractures had the highest excess cost: men $44,963 (95 % CI: $38,498-51,428) and women $45,715 (95 % CI: $36,998-54,433). Prevalent fractures (other than miscellaneous or wrist fractures) also had significant excess costs. No significant excess costs existed for nonfracture osteoporosis. Significant excess costs exist for patients with incident fractures and with prevalent hip, vertebral, humerus, multiple, and traumatic fractures. Ignoring prevalent fractures underestimate the true cost of osteoporosis. |
Author | Goeree, R. Hopkins, R. B. Azimaee, M. Morin, S. Lix, L. M. Pullenayegum, E. Papaioannou, A. Thabane, L. Tarride, J. E. Finlayson, G. Leslie, W. D. Adachi, J. D. Metge, C. |
Author_xml | – sequence: 1 givenname: R. B. surname: Hopkins fullname: Hopkins, R. B. email: hopkinr@mcmaster.ca organization: Department of Clinical Epidemiology and Biostatistics, Faculty of Health Science, McMaster University, Programs for Assessment of Technology in Health, St. Joseph’s Healthcare–Hamilton – sequence: 2 givenname: J. E. surname: Tarride fullname: Tarride, J. E. organization: Department of Clinical Epidemiology and Biostatistics, Faculty of Health Science, McMaster University, Programs for Assessment of Technology in Health, St. Joseph’s Healthcare–Hamilton, Centre for Evaluation of Medicines – sequence: 3 givenname: W. D. surname: Leslie fullname: Leslie, W. D. organization: University of Manitoba – sequence: 4 givenname: C. surname: Metge fullname: Metge, C. organization: University of Manitoba – sequence: 5 givenname: L. M. surname: Lix fullname: Lix, L. M. organization: School of Public Health, University of Saskatchewan – sequence: 6 givenname: S. surname: Morin fullname: Morin, S. organization: Department of Medicine, McGill University – sequence: 7 givenname: G. surname: Finlayson fullname: Finlayson, G. organization: University of Manitoba – sequence: 8 givenname: M. surname: Azimaee fullname: Azimaee, M. organization: University of Manitoba – sequence: 9 givenname: E. surname: Pullenayegum fullname: Pullenayegum, E. organization: Department of Clinical Epidemiology and Biostatistics, Faculty of Health Science, McMaster University, Centre for Evaluation of Medicines, Biostatistics Unit, St. Joseph’s Healthcare–Hamilton – sequence: 10 givenname: R. surname: Goeree fullname: Goeree, R. organization: Department of Clinical Epidemiology and Biostatistics, Faculty of Health Science, McMaster University, Programs for Assessment of Technology in Health, St. Joseph’s Healthcare–Hamilton, Centre for Evaluation of Medicines – sequence: 11 givenname: J. D. surname: Adachi fullname: Adachi, J. D. organization: Department of Medicine, McMaster University – sequence: 12 givenname: A. surname: Papaioannou fullname: Papaioannou, A. organization: Department of Medicine, McMaster University – sequence: 13 givenname: L. surname: Thabane fullname: Thabane, L. organization: Department of Clinical Epidemiology and Biostatistics, Faculty of Health Science, McMaster University, Centre for Evaluation of Medicines, Biostatistics Unit, St. Joseph’s Healthcare–Hamilton |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22572964$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkU1rVTEQhoNU7G31B7iRgBsXHs13TjZCKfUDCm4U3IXcJOfelHOTY3JO1X_vXG9bakFwFWbmmTcz856go1xyROg5JW8oIfptI4SaviOUddQY3elHaEUF5x0zSh6hFTFcd0bQb8fopLUrAj2APUHHjEkNjFihdtHmtHNzyhs8byOOP31sDfvS5oaHUvEEtZgh-JHmLU7ZpwAhHqrz81Jje42nGq_d-CDpcsAw7W0Gg14sU6mlpfYUPR7c2OKzm_cUfX1_8eX8Y3f5-cOn87PLzkvC525NvCJBDn3PnPEhCMWFH6RTujeaQz4IQZwOVEQp1bpXcm24Yl4Ewp0wjp-idwfdaVnvYvAwYnWjnSosXH_Z4pL9u5LT1m7KtZWUEk4NCLy6Eajl-xLbbHep-TiOLseyNEuZoYr0lNH_QHvWc861AvTlA_SqLDXDJf5QjAnaa6DogfJws1bjcDc3JXbvvj24b8F9u3ff7nte3F_4ruPWbgDYAWhQyptY7339T9XfReq-tQ |
CitedBy_id | crossref_primary_10_1186_1471_2318_14_130 crossref_primary_10_1016_j_puhe_2023_10_022 crossref_primary_10_1007_s00198_021_05935_1 crossref_primary_10_1016_j_berh_2020_101548 crossref_primary_10_1007_s00198_014_2652_2 crossref_primary_10_1310_sci2004_302 crossref_primary_10_1016_j_jocd_2015_07_004 crossref_primary_10_1007_s00198_021_05877_8 crossref_primary_10_1093_jbmr_zjae014 crossref_primary_10_1080_09638288_2016_1262467 crossref_primary_10_1038_bonekey_2013_101 crossref_primary_10_1155_2018_5178284 crossref_primary_10_1186_1471_2318_13_130 crossref_primary_10_1002_jbmr_2028 crossref_primary_10_1177_1759720X13500862 crossref_primary_10_1007_s00198_013_2505_4 crossref_primary_10_1007_s00198_016_3631_6 crossref_primary_10_1080_03007995_2017_1383889 crossref_primary_10_2106_JBJS_20_00795 crossref_primary_10_1155_2019_5359204 crossref_primary_10_1111_1753_6405_12381 crossref_primary_10_1093_ageing_afu156 crossref_primary_10_1177_1054773815577577 crossref_primary_10_1177_2309499019875262 crossref_primary_10_1007_s11657_020_00816_2 crossref_primary_10_1007_s00198_016_3596_5 crossref_primary_10_4274_meandros_galenos_2023_22043 crossref_primary_10_1177_1759720X14523500 crossref_primary_10_1002_jbmr_3640 crossref_primary_10_1007_s10439_016_1724_1 crossref_primary_10_1097_MD_0000000000011470 crossref_primary_10_3390_ijerph18189831 crossref_primary_10_1007_s00256_019_03212_1 crossref_primary_10_2106_JBJS_16_01042 crossref_primary_10_1007_s10742_013_0112_7 crossref_primary_10_1007_s00198_013_2321_x crossref_primary_10_1302_2058_5241_3_160088 |
Cites_doi | 10.1007/s00198-003-1385-4 10.1111/j.1524-4733.2006.00161.x 10.1586/erp.10.41 10.1345/aph.18117 10.1136/bmj.320.7243.1197 10.1002/jbmr.457 10.1007/s001980170116 10.1002/(SICI)1099-1050(199607)5:4<297::AID-HEC216>3.0.CO;2-T 10.1007/s00198-010-1464-2 10.2165/00019053-200624090-00005 10.1080/17453670710015094 10.2165/11531040-000000000-00000 10.1097/MLR.0b013e31815c3b6c 10.1007/s00198-004-1694-2 10.1016/j.jclinepi.2005.08.017 10.1016/j.jclinepi.2007.11.006 10.1007/s11926-010-0097-y 10.1002/(SICI)1097-0258(19991215)18:23<3245::AID-SIM314>3.0.CO;2-2 10.1093/oso/9780198526629.001.0001 10.1016/S1499-2671(09)31007-2 |
ContentType | Journal Article |
Copyright | International Osteoporosis Foundation and National Osteoporosis Foundation 2012 International Osteoporosis Foundation and National Osteoporosis Foundation 2013 |
Copyright_xml | – notice: International Osteoporosis Foundation and National Osteoporosis Foundation 2012 – notice: International Osteoporosis Foundation and National Osteoporosis Foundation 2013 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QP 7RV 7TS 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1007/s00198-012-1997-7 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database (ProQuest) Physical Education Index Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database (Proquest) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland AUTh Library subscriptions: ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Central China ProQuest Hospital Collection (Alumni) Physical Education Index ProQuest Central Nursing & Allied Health Premium ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Calcium & Calcified Tissue Abstracts ProQuest Public Health MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1433-2965 |
EndPage | 593 |
ExternalDocumentID | 2876922041 10_1007_s00198_012_1997_7 22572964 |
Genre | Journal Article |
GeographicLocations | Manitoba Manitoba Canada |
GeographicLocations_xml | – name: Manitoba – name: Manitoba Canada |
GrantInformation_xml | – fundername: Canadian Institutes of Health Research grantid: 88225-1 |
GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 123 199 1N0 1SB 203 28- 29O 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 408 409 40D 40E 53G 5QI 5RE 5VS 67Z 6NX 78A 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AAKSU AANXM AANZL AAPBV AARHV AARTL AATNV AATVU AAUYE AAWCG AAWTL AAYFA AAYIU AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKAS ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABOCM ABPLI ABPTK ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFS ACHSB ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACTTH ACUDM ACVWB ACWMK ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEEQQ AEFIE AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFAFS AFEXP AFKRA AFLOW AFNRJ AFQWF AFWTZ AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGKHE AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP EBD EBLON EBS EIOEI EJD EN4 ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH L7B LAS LLZTM M1P M4Y MA- N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOW YLTOR Z45 Z7S Z7U Z7V Z7W Z7X Z81 Z82 Z83 Z87 Z8N Z8O Z8P Z8Q Z8U Z8V Z8W Z91 ZMTXR ZOVNA ZXP ~A9 ~EX ~KM AACDK AAEOY AAJBT AASML AAYZH ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU AJOOF ALIPV CGR CUY CVF ECM EIF EMB EMOBN H13 NPM SV3 AAYXX CITATION 7QP 7TS 7XB 8FK K9. PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c503t-b0c60d5f882a9cdd4634cf5a6789735f8d440a7d14e556b865b9362c4d03a49a3 |
IEDL.DBID | AEJHL |
ISSN | 0937-941X |
IngestDate | Tue Sep 17 21:18:16 EDT 2024 Sat Oct 26 00:11:43 EDT 2024 Fri Oct 25 00:41:15 EDT 2024 Thu Oct 10 20:40:30 EDT 2024 Thu Nov 21 22:00:12 EST 2024 Tue Oct 15 23:41:59 EDT 2024 Sat Dec 16 12:02:51 EST 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Osteoporosis Excess cost Fracture Cost of illness |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c503t-b0c60d5f882a9cdd4634cf5a6789735f8d440a7d14e556b865b9362c4d03a49a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5110319 |
PMID | 22572964 |
PQID | 1282224187 |
PQPubID | 33762 |
PageCount | 13 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5110319 proquest_miscellaneous_1291608121 proquest_miscellaneous_1282833376 proquest_journals_1282224187 crossref_primary_10_1007_s00198_012_1997_7 pubmed_primary_22572964 springer_journals_10_1007_s00198_012_1997_7 |
PublicationCentury | 2000 |
PublicationDate | 2013-02-01 |
PublicationDateYYYYMMDD | 2013-02-01 |
PublicationDate_xml | – month: 02 year: 2013 text: 2013-02-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationSubtitle | With other metabolic bone diseases |
PublicationTitle | Osteoporosis international |
PublicationTitleAbbrev | Osteoporos Int |
PublicationTitleAlternate | Osteoporos Int |
PublicationYear | 2013 |
Publisher | Springer-Verlag Springer Nature B.V |
Publisher_xml | – name: Springer-Verlag – name: Springer Nature B.V |
References | Willan, O’Brien (CR27) 1996; 5 CR19 CR18 Orsini, Rousculp, Long, Wang (CR9) 2005; 16 CR15 Finlayson, Ekuma, Yogendran, Burland, Forget (CR23) 2010 CR14 Leslie, Lix, Langsetmo, Berger, Goltzman, Hanley, Adachi, Johansson, Oden, McCloskey, Kanis (CR1) 2011; 22 Poss, Hirdes, Fries, McKillop, Chase (CR17) 2008; 46 Briggs, Claxton, Sculpher (CR21) 2006 Thompson, Barber (CR28) 2000; 320 Kozyrskyj, Mustard (CR16) 1998; 32 Wiktorowicz, Goeree, Papaioannou, Adachi, Papadimitropoulos (CR7) 2001; 12 Pike, Birnbaum, Schiller, Sharma, Burge, Edgell (CR10) 2010; 28 CR2 Strom, Borgstrom, Zethraeus, Johnell, Lidgren, Ponzer, Svensson, Abdon, Ornstein, Ceder, Thorngren, Sernbo, Jonsson (CR5) 2008; 79 Leslie, Metge, Azimaee, Lix, Finlayson, Morin, Caetano (CR6) 2011; 26 Knottnerus, Tugwell (CR13) 2008; 61 Becker, Kilgore, Morrisey (CR3) 2010; 12 CR25 Goeree, O’Reilly, Hux, Lim, Hopkins, Tarride, Blackhouse, Xie (CR22) 2009; 33 CR24 Goeree, O’Reilly, Hopkins, Blackhouse, Tarride, Xie, Lim (CR12) 2010; 10 Wiebe, Vandermeer, Platt, Klassen, Moher, Barrowman (CR20) 2006; 59 Rousculp, Long, Wang, Schoenfeld, Meadows (CR11) 2007; 10 Briggs, Mooney, Wonderling (CR26) 1999; 18 Akobundu, Ju, Blatt, Mullins (CR4) 2006; 24 Melton, Gabriel, Crowson, Tosteson, Johnell, Kanis (CR8) 2003; 14 20402541 - Pharmacoeconomics. 2010;28(5):395-409 15340799 - Osteoporos Int. 2005 Apr;16(4):359-71 18484255 - Acta Orthop. 2008 Apr;79(2):269-80 10602149 - Stat Med. 1999 Dec 15;18(23):3245-62 9825079 - Ann Pharmacother. 1998 Nov;32(11):1152-7 18362817 - Med Care. 2008 Apr;46(4):380-7 20425518 - Curr Rheumatol Rep. 2010 Jun;12(3):186-91 11420776 - Osteoporos Int. 2001;12(4):271-8 20715915 - Expert Rev Pharmacoecon Outcomes Res. 2010 Aug;10(4):379-84 10784550 - BMJ. 2000 Apr 29;320(7243):1197-200 17391423 - Value Health. 2007 Mar-Apr;10(2):144-52 8880166 - Health Econ. 1996 Jul-Aug;5(4):297-305 12730750 - Osteoporos Int. 2003 Jun;14(5):383-8 21161509 - Osteoporos Int. 2011 Mar;22(3):817-27 16942122 - Pharmacoeconomics. 2006;24(9):869-90 18313555 - J Clin Epidemiol. 2008 Apr;61(4):323 21713989 - J Bone Miner Res. 2011 Oct;26(10):2419-29 16549255 - J Clin Epidemiol. 2006 Apr;59(4):342-53 AL Kozyrskyj (1997_CR16) 1998; 32 C Pike (1997_CR10) 2010; 28 1997_CR19 O Strom (1997_CR5) 2008; 79 MD Rousculp (1997_CR11) 2007; 10 LJ Melton III (1997_CR8) 2003; 14 AH Briggs (1997_CR26) 1999; 18 JW Poss (1997_CR17) 2008; 46 R Goeree (1997_CR22) 2009; 33 1997_CR15 1997_CR18 1997_CR14 G Finlayson (1997_CR23) 2010 N Wiebe (1997_CR20) 2006; 59 E Akobundu (1997_CR4) 2006; 24 AR Willan (1997_CR27) 1996; 5 R Goeree (1997_CR12) 2010; 10 A Knottnerus (1997_CR13) 2008; 61 LS Orsini (1997_CR9) 2005; 16 DJ Becker (1997_CR3) 2010; 12 SG Thompson (1997_CR28) 2000; 320 ME Wiktorowicz (1997_CR7) 2001; 12 AH Briggs (1997_CR21) 2006 WD Leslie (1997_CR1) 2011; 22 1997_CR2 1997_CR24 WD Leslie (1997_CR6) 2011; 26 1997_CR25 |
References_xml | – volume: 14 start-page: 383 year: 2003 end-page: 388 ident: CR8 article-title: Cost-equivalence of different osteoporotic fractures publication-title: Osteoporos Int doi: 10.1007/s00198-003-1385-4 contributor: fullname: Kanis – volume: 10 start-page: 144 year: 2007 end-page: 152 ident: CR11 article-title: Economic burden of osteoporosis-related fractures in Medicaid publication-title: Value Health doi: 10.1111/j.1524-4733.2006.00161.x contributor: fullname: Meadows – ident: CR18 – volume: 10 start-page: 379 year: 2010 end-page: 384 ident: CR12 article-title: General population versus disease-specific event rate and cost estimates: potential bias for economic appraisals publication-title: Expert Rev Pharmacoecon Outcomes Res doi: 10.1586/erp.10.41 contributor: fullname: Lim – volume: 32 start-page: 1152 year: 1998 end-page: 1157 ident: CR16 article-title: Validation of an electronic, population-based prescription database publication-title: Ann Pharmacother doi: 10.1345/aph.18117 contributor: fullname: Mustard – volume: 33 start-page: 35 year: 2009 end-page: 45 ident: CR22 article-title: Total and excess costs of diabetes and related complications in Ontario publication-title: Can J Diabetes contributor: fullname: Xie – volume: 320 start-page: 1197 year: 2000 end-page: 2000 ident: CR28 article-title: How should cost data in pragmatic randomised trials be analysed? publication-title: BMJ doi: 10.1136/bmj.320.7243.1197 contributor: fullname: Barber – ident: CR14 – ident: CR2 – volume: 26 start-page: 2419 issue: 10 year: 2011 end-page: 2429 ident: CR6 article-title: Direct costs of fractures in Canada and trends 1996–2006: a population-based cost-of-illness analysis publication-title: J Bone Miner Res doi: 10.1002/jbmr.457 contributor: fullname: Caetano – volume: 12 start-page: 271 year: 2001 end-page: 278 ident: CR7 article-title: Economic implications of hip fracture: health service use, institutional care and cost in Canada publication-title: Osteoporos Int doi: 10.1007/s001980170116 contributor: fullname: Papadimitropoulos – year: 2010 ident: CR23 publication-title: The additional cost of chronic disease in Manitoba contributor: fullname: Forget – ident: CR25 – volume: 5 start-page: 297 year: 1996 end-page: 305 ident: CR27 article-title: Confidence intervals for cost-effectiveness ratios: an application of Fieller’s theorem publication-title: Health Econ doi: 10.1002/(SICI)1099-1050(199607)5:4<297::AID-HEC216>3.0.CO;2-T contributor: fullname: O’Brien – volume: 22 start-page: 817 year: 2011 end-page: 827 ident: CR1 article-title: Construction of a FRAX(R) model for the assessment of fracture probability in Canada and implications for treatment publication-title: Osteoporos Int doi: 10.1007/s00198-010-1464-2 contributor: fullname: Kanis – volume: 24 start-page: 869 year: 2006 end-page: 890 ident: CR4 article-title: Cost-of-illness studies: a review of current methods publication-title: PharmacoEconomics doi: 10.2165/00019053-200624090-00005 contributor: fullname: Mullins – volume: 79 start-page: 269 year: 2008 end-page: 280 ident: CR5 article-title: Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden publication-title: Acta Orthop doi: 10.1080/17453670710015094 contributor: fullname: Jonsson – volume: 28 start-page: 395 year: 2010 end-page: 409 ident: CR10 article-title: Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US publication-title: PharmacoEconomics doi: 10.2165/11531040-000000000-00000 contributor: fullname: Edgell – ident: CR19 – volume: 46 start-page: 380 year: 2008 end-page: 387 ident: CR17 article-title: Validation of Resource Utilization Groups version III for Home Care (RUG-III/HC): evidence from a Canadian home care jurisdiction publication-title: Med Care doi: 10.1097/MLR.0b013e31815c3b6c contributor: fullname: Chase – ident: CR15 – volume: 16 start-page: 359 year: 2005 end-page: 371 ident: CR9 article-title: Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures publication-title: Osteoporos Int doi: 10.1007/s00198-004-1694-2 contributor: fullname: Wang – volume: 59 start-page: 342 year: 2006 end-page: 353 ident: CR20 article-title: A systematic review identifies a lack of standardization in methods for handling missing variance data publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2005.08.017 contributor: fullname: Barrowman – volume: 61 start-page: 323 year: 2008 ident: CR13 article-title: STROBE—a checklist to strengthen the reporting of observational studies in epidemiology publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2007.11.006 contributor: fullname: Tugwell – volume: 12 start-page: 186 year: 2010 end-page: 191 ident: CR3 article-title: The societal burden of osteoporosis publication-title: Curr Rheumatol Rep doi: 10.1007/s11926-010-0097-y contributor: fullname: Morrisey – ident: CR24 – volume: 18 start-page: 3245 year: 1999 end-page: 3262 ident: CR26 article-title: Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation publication-title: Stat Med doi: 10.1002/(SICI)1097-0258(19991215)18:23<3245::AID-SIM314>3.0.CO;2-2 contributor: fullname: Wonderling – year: 2006 ident: CR21 publication-title: Decision modelling for health economic evaluation contributor: fullname: Sculpher – ident: 1997_CR15 – volume: 26 start-page: 2419 issue: 10 year: 2011 ident: 1997_CR6 publication-title: J Bone Miner Res doi: 10.1002/jbmr.457 contributor: fullname: WD Leslie – volume: 18 start-page: 3245 year: 1999 ident: 1997_CR26 publication-title: Stat Med doi: 10.1002/(SICI)1097-0258(19991215)18:23<3245::AID-SIM314>3.0.CO;2-2 contributor: fullname: AH Briggs – volume: 22 start-page: 817 year: 2011 ident: 1997_CR1 publication-title: Osteoporos Int doi: 10.1007/s00198-010-1464-2 contributor: fullname: WD Leslie – ident: 1997_CR19 – volume: 12 start-page: 271 year: 2001 ident: 1997_CR7 publication-title: Osteoporos Int doi: 10.1007/s001980170116 contributor: fullname: ME Wiktorowicz – volume: 61 start-page: 323 year: 2008 ident: 1997_CR13 publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2007.11.006 contributor: fullname: A Knottnerus – volume: 12 start-page: 186 year: 2010 ident: 1997_CR3 publication-title: Curr Rheumatol Rep doi: 10.1007/s11926-010-0097-y contributor: fullname: DJ Becker – volume: 320 start-page: 1197 year: 2000 ident: 1997_CR28 publication-title: BMJ doi: 10.1136/bmj.320.7243.1197 contributor: fullname: SG Thompson – volume-title: Decision modelling for health economic evaluation year: 2006 ident: 1997_CR21 doi: 10.1093/oso/9780198526629.001.0001 contributor: fullname: AH Briggs – volume: 24 start-page: 869 year: 2006 ident: 1997_CR4 publication-title: PharmacoEconomics doi: 10.2165/00019053-200624090-00005 contributor: fullname: E Akobundu – volume: 33 start-page: 35 year: 2009 ident: 1997_CR22 publication-title: Can J Diabetes doi: 10.1016/S1499-2671(09)31007-2 contributor: fullname: R Goeree – ident: 1997_CR25 – volume-title: The additional cost of chronic disease in Manitoba year: 2010 ident: 1997_CR23 contributor: fullname: G Finlayson – ident: 1997_CR14 – ident: 1997_CR2 – volume: 46 start-page: 380 year: 2008 ident: 1997_CR17 publication-title: Med Care doi: 10.1097/MLR.0b013e31815c3b6c contributor: fullname: JW Poss – volume: 10 start-page: 144 year: 2007 ident: 1997_CR11 publication-title: Value Health doi: 10.1111/j.1524-4733.2006.00161.x contributor: fullname: MD Rousculp – volume: 10 start-page: 379 year: 2010 ident: 1997_CR12 publication-title: Expert Rev Pharmacoecon Outcomes Res doi: 10.1586/erp.10.41 contributor: fullname: R Goeree – volume: 5 start-page: 297 year: 1996 ident: 1997_CR27 publication-title: Health Econ doi: 10.1002/(SICI)1099-1050(199607)5:4<297::AID-HEC216>3.0.CO;2-T contributor: fullname: AR Willan – volume: 59 start-page: 342 year: 2006 ident: 1997_CR20 publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2005.08.017 contributor: fullname: N Wiebe – volume: 14 start-page: 383 year: 2003 ident: 1997_CR8 publication-title: Osteoporos Int doi: 10.1007/s00198-003-1385-4 contributor: fullname: LJ Melton III – ident: 1997_CR18 – volume: 28 start-page: 395 year: 2010 ident: 1997_CR10 publication-title: PharmacoEconomics doi: 10.2165/11531040-000000000-00000 contributor: fullname: C Pike – volume: 16 start-page: 359 year: 2005 ident: 1997_CR9 publication-title: Osteoporos Int doi: 10.1007/s00198-004-1694-2 contributor: fullname: LS Orsini – volume: 79 start-page: 269 year: 2008 ident: 1997_CR5 publication-title: Acta Orthop doi: 10.1080/17453670710015094 contributor: fullname: O Strom – volume: 32 start-page: 1152 year: 1998 ident: 1997_CR16 publication-title: Ann Pharmacother doi: 10.1345/aph.18117 contributor: fullname: AL Kozyrskyj – ident: 1997_CR24 |
SSID | ssj0007997 |
Score | 2.3193698 |
Snippet | Summary
Based on a population age 50+, significant excess costs relative to matched controls exist for patients with incident fractures that are similar in... Based on a population age 50+, significant excess costs relative to matched controls exist for patients with incident fractures that are similar in relative... SUMMARYBased on a population age 50+, significant excess costs relative to matched controls exist for patients with incident fractures that are similar in... |
SourceID | pubmedcentral proquest crossref pubmed springer |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 581 |
SubjectTerms | Age Aged Aged, 80 and over Asthma Bone mineral density Case-Control Studies Chronic obstructive pulmonary disease Endocrinology Female Fractures Health Care Costs - statistics & numerical data Health care expenditures Health Resources - utilization Health Services Research - methods Heart diseases Hip Humans Humerus Incidence Male Manitoba - epidemiology Medicine Medicine & Public Health Middle Aged Original Article Orthopedics Osteoporosis Osteoporosis - economics Osteoporosis - epidemiology Osteoporosis, Postmenopausal - economics Osteoporosis, Postmenopausal - epidemiology Osteoporotic Fractures - economics Osteoporotic Fractures - epidemiology Out of pocket costs Prevalence Resource utilization Rheumatology Sex Factors Stroke Vertebrae Wrist |
Title | Estimating the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis |
URI | https://link.springer.com/article/10.1007/s00198-012-1997-7 https://www.ncbi.nlm.nih.gov/pubmed/22572964 https://www.proquest.com/docview/1282224187 https://search.proquest.com/docview/1282833376 https://search.proquest.com/docview/1291608121 https://pubmed.ncbi.nlm.nih.gov/PMC5110319 |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB7xkCouFCiUtIBciVPboCR24viIyqIVgl6gErfIr8CqUoLIrsTPZyabRF0oSHDJwR4ljj3j-TwvAxxaZSJvyLyE-iMUnotQG63D0msuTexjZcngNr6Uv6_zkxGVyUkG00X196j3SLYb9ZDrRmCE4q6SNjYilMuwiqonRd5ePR6djc-H_Veq9koVPKrLUIn4uvdl_u8li9roGcR8Hin5xF3aaqHTj-8Z_wasd5iTHc-ZZBOWfLUFHy46r_onaEYo54RcqxuGeJD5B8odYLZupg1DUMu64qsNI6stI-s8pfeykjKsZnhe_8nu7qls-JNGXTlW1VXfwiifpEa8XzeTZhv-nI6ufo3D7jKG0KYRn4Ymslnk0hIRuVbWOZFxYctUo7JTkmO7EyLS0sXCp2lm8iw1CpWjFS7iWijNd2AFP-l3gXmEQZZzY0vEBjJxBp_WaWdyK1TmRQDf-0Up7uY1N4qhunI7jQVOY0HTWMgA9vplKzrxa4qYgmMRm-TY_W3oRsEhb4iufD2b0-Sc4wb7Gg2iZwRNSRzA5zknDCPCjVCSzzoAucAjAwEV7l7sqSa3bQFvBLmUPBbAj55V_hn6Sz_65U3UX2EtaS_uoMCbPViZ3s_8Piw3bnbQycsjnAYS8A |
link.rule.ids | 230,315,782,786,887,27933,27934,41073,42142,48344,48347,48357,49649,49652,49662,52153 |
linkProvider | Springer Nature |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB7xkFouQB9AeLRG6qltpGTtxPERwS6LClzYStwiv9JySRDZlfj5zGSTiIUWCS452KMktmc8n-dlgG9WmcgbMi-h_giF5yLURuuw8JpLE_tYWTK4ja_k5XV2MqQyObzLhWmi3TuXZLNT98luhEYo8GrQBEeEchlWhUoFsvLq0dnkdNRvwFI1d6rgWV2GSsTXnTPzXy9ZVEfPMObzUMkn_tJGDY023jSATVhvUSc7mrPJB1jy5Ud4d9H61T9BPURJJ-xa_mGICJm_p-wBZqt6WjOEtawtv1ozstsyss9Tgi8rKMdqhif2n-z2jgqHP2nUpWNlVXYtjDJKKkT8VX1Tf4bfo-HkeBy21zGENon4NDSRTSOXFIjJtbLOiZQLWyQa1Z2SHNudEJGWLhY-SVKTpYlRqB6tcBHXQmm-BSv4Sb8DzCMQspwbWyA6kANn8GmddiazuKReBPC9W5X8dl51I-_rKzfTmOM05jSNuQxgv1u3vBXAOo8pPBbRSYbdh303ig75Q3Tpq9mcJuMct9iXaBA_I2waxAFsz1mh_yPcCiV5rQOQC0zSE1Dp7sWe8uZvU8IbYS6ljwXwo2OVR7_-v4Huvor6K7wfTy7O8_Ozy197sDZorvGgMJx9WJnezfwBLNdu9qUVngcIthbg |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Ja9wwFH5kgdBLl3SJ27RRoKe2ZuyRbFmnEJoZJiuFtpCb0eYmF3uIZ6A_v-95I5O0hZCLD9LDtqQnve-tAvholYm8IfMSyo9QeC5CbbQOC6-5NLGPlSWD2-y7vLjMjiZUJuegz4Vpot17l2Sb00BVmsrFaO6K0ZD4RsiEgrDGTaBEKNdhU6Aig4y-eTg5mZ0Nh7FUzf0qqLfLUIn4snds_u0lq6LpHt68HzZ5x3faiKTps0cP5jk87dAoO2zZ5wWs-XIbts47f_tLqCd4AhCmLX8xRIrM_6asAmarelEzhLusK8taM7LnMrLbU-IvKyj3aoma_Bc2v6GC4ncadelYWZV9C6NMkwo1gaq-rl_Bz-nkx9dZ2F3TENok4ovQRDaNXFIgVtfKOidSLmyRaBSDSnJsd0JEWrpY-CRJTZYmRqHYtMJFXAul-WvYwE_6HWAeAZLl3NgCUYMcO4NP67QzmRUq9SKAT_0K5fO2Gkc-1F1upjHHacxpGnMZwG6_hnm3Mes8prBZRC0Zdu8P3bilyE-iS18tW5qMczx6_0eDuBrh1DgO4E3LFsMf4REpyZsdgFxhmIGASnqv9pTXV01pb4S_lFYWwOeebW79-r8G-vZB1Huw9e1omp8dX5y-gyfj5nYPis7ZhY3FzdK_h_XaLT90--gPVCkfow |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Estimating+the+excess+costs+for+patients+with+incident+fractures%2C+prevalent+fractures%2C+and+nonfracture+osteoporosis&rft.jtitle=Osteoporosis+international&rft.au=Hopkins%2C+R.+B.&rft.au=Tarride%2C+J.+E.&rft.au=Leslie%2C+W.+D.&rft.au=Metge%2C+C.&rft.date=2013-02-01&rft.pub=Springer-Verlag&rft.issn=0937-941X&rft.eissn=1433-2965&rft.volume=24&rft.issue=2&rft.spage=581&rft.epage=593&rft_id=info:doi/10.1007%2Fs00198-012-1997-7&rft.externalDocID=10_1007_s00198_012_1997_7 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0937-941X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0937-941X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0937-941X&client=summon |